Developing Topics.

Background: It has been more than 20 years for a new treatment for Alzheimer's Disease (AD) to emerge. This treatment has recently been in the form of a monoclonal antibody targeting the end-products of neuronal death. We are testing the safety of a novel approach using activated stem cells injected directly into the ventricles of the brain.

Human intracerebroventricular (ICV) injection of autologous, non-engineered, adipose-derived stromal vascular fraction (ADSVF) for neurodegenerative disorders: results of a 3-year phase 1 study of 113 injections in 31 patients.

We have chosen to test the safety of human intracerebroventricular (ICV) brain injections of autologous non-genetically-modified adipose-derived stromal vascular fraction (ADSVF). In this IRB-approved trial, 24 patients received ICV ADSVF via an implanted reservoir between 5/22/14 and 5/22/17. Seven others were injected via their ventriculo-peritoneal shunts.